C12N 2760/12271
Demonstrated in vivo effect
C12N2760/12271 (Demonstrated in vivo effect) appears on 3 US grants and 4 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 4
- Assignees
- 7
- Inventors
- 19
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 0 | 1 |
| 2024 | 0 | 0 |
| 2025 | 1 | 0 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof24 Mar 2026US 12,584,116 B2Consejo Superior De Investigaciones Cientificas (Csic)
- DNA vaccine against crimean-congo hemorrhagic fever virus (CCHFV)13 May 2025US 12,296,001 B2The Wistar Institute of Anatomy and Biology
- Rift valley fever virus replicon particles and use thereof27 Jun 2017US 9,687,542 B2The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
- Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof6 Jul 2023US 2023/0212529 A1Instituto Nacional de Investigacion y Tecnologia Agraria y Alimentaria (INIA)
- A novel dna vaccine against crimean-congo hemorrhagic fever virus (cchfv)30 Dec 2021US 2021/0401965 A1The Wistar Institute of Anatomy and Biology
- Vaccine Composition for Preventing or Treating Diseases Caused by Severe Fever with Thrombocytopenia Syndrome (SFTS) Viral Infection22 Jul 2021US 2021/0220464 A1Geneone Life Science, Inc.
- Rift valley fever virus replicon particles and use thereof16 Jul 2015US 2015/0196630 A1The Government of the United States of America as represented by the Secretary of the Department of
Most cited
By later US patents